The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

When it comes to muscular diseases, most of us have heard of especially common ones like muscular dystrophy and Lou Gehrig's disease. But one of the rarest muscular disorders is also one of the most ...

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

For decades, treatment of peripheral artery disease has focused almost exclusively on restoring blood flow. Now, new research ...

Muscle ultrasound has emerged as a pivotal, non‐invasive imaging modality that offers real‐time insights into muscle structure and pathology. This technique enables both qualitative and quantitative ...

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative method known as TEVs-TTN, for studying the specific mechanical functions of proteins through their ...

All parents will now be offered spinal muscular atrophy screening for their newborns.

Researchers in public health have reported in the first broad study in the United States the frequency of two muscle-weakness disorders that strike mostly boys: Duchenne muscular dystrophy and Becker ...

Pathologic changes of the X-chromosome gene for dystrophin give rise to Duchenne muscular dystrophy (DMD), and dystrophin -- which minimizes muscle fiber loss due to sarcolemma contraction damage when ...

A new study suggests that building muscle strength could play a direct role in reducing depression risk, particularly in ...